Credit: Getty Images. The recall was initiated due to product stability testing results that did not meet specifications for iron content. Allergan has expanded its December 2017 voluntary recall of ...

Iron deficiency is common in hemodialysis patients for several reasons. These include substantial losses of blood caused by taking frequent blood samples for analysis, blood remaining in the dialysis ...

For a monthly blood loss of 420 mL, the cost was $174,400 with IV iron dextran compared with $157,000 with oral ferrous sulfate, and the effectiveness was 18.91 and 17.19, respectively. The use of ...

IV iron dextran is most cost-effective, yielding 19.26 QALYs compared with 19.10 QALYs for oral ferrous sulfate. (HealthDay News) — Intravenous (IV) iron dextran is the most cost-effective strategy ...

Intravenous (IV) iron use overall is associated with a “very low” risk for anaphylaxis, but iron dextran and ferumoxytol carry an increased risk relative to iron sucrose, according to new research.

THE development of sarcomas in rats after the repeated administration of massive doses of iron-dextran complex has been reported by Richmond 1 and confirmed by Haddow and Horning. 2 The latter were ...

China Medical System Holdings Limited (“CMS” or the “Group”) is pleased to announce that, the Group through its wholly-owned subsidiary entered into an exclusive commercialization and supply agreement ...

During a period of rapid fluctuation in the intravenous iron market, there was increased use of a more expensive drug that afforded providers additional revenue. Objectives: Medicare Part B payment ...

A single dose of intravenous (IV) iron dextran is the cost-effective treatment for women with heavy menstrual bleeding and iron deficiency anemia (IDA), according to new research published in Blood ...